New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:58 EDTVRX, AGNAllergan has many other strategic options, says BMO Capital
After meeting with Allergan's (AGN) management, BMO Capital says that the company has many strategic options other than the takeover bid from Valeant (VRX). The firm thinks that Allergan's outlook as a standalone company is strong, and it believes there is less than a 50% chance that Valeant will acquire Allergan. The firm keeps an Outperform rating on Allergan.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use